论文部分内容阅读
目的:评价依达拉奉治疗发病72h内脑梗死的疗效。方法:100例72h内发病的急性脑梗死患者随机分成两组,两组均用葛根素注射液0.4g加入生理盐水中静脉滴注,治疗组在此基础上再加用依达拉奉30mg加入生理盐水100mL静脉滴注,每日两次,14d为1疗程。评价治疗前后神经功能缺失评分和日常生活能力的变化及疗效,监测用药前后肝肾功能的变化。结果:治疗组14d后神经功能显著改善,与对照组相比差异有显著性(P=0.004),至21d差异更显著(P=0.003),治疗组有效率(76.00%)明显高于对照组(58.00%);治疗组治疗14d的日常生活能力明显改善,与对照组相比差异有显著性(P<0.05),至60d差异更显著,治疗组有效率(70.00%)明显高于对照组(54.00%),两组患者治疗前后肝肾功能指标无明显改变。结论:依达拉奉治疗急性脑梗死是安全有效的。
Objective: To evaluate the efficacy of edaravone in the treatment of cerebral infarction within 72 hours of onset. Methods: One hundred patients with acute cerebral infarction within 72 hours were randomly divided into two groups. Both groups were given intravenous drip of 0.4g puerarin injection and normal saline. The treatment group was treated with edaravone 30mg 100mL saline intravenously, twice daily, 14d for a course of treatment. Before and after treatment to evaluate the neurological deficit score and daily living ability changes and efficacy, monitoring of liver and kidney function changes before and after treatment. Results: After 14 days, the neurological function of the treatment group was significantly improved (P = 0.004), the difference was significant at 21 days (P = 0.003), and the effective rate of the treatment group (76.00%) was significantly higher than that of the control group (58.00%). The daily living ability of the treatment group on the 14th day after treatment was significantly improved (P <0.05), and the difference was more significant on the 60th day. The effective rate (70.00%) in the treatment group was significantly higher than that in the control group (54.00%). There was no significant change of liver and kidney function before and after treatment in both groups. Conclusion: Edaravone is safe and effective in the treatment of acute cerebral infarction.